PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Retifanlimab Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma MOST POPULAR Lung-Sparing Surgery Is Effective for Some with Early-Stage Lung Cancer March 9, 2023 New treatment for Waldenstrom’s macroglobulinaemia in England October 1, 2022 A More Treatable Kind of Metastatic Cancer? October 5, 2020 Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... November 21, 2020 Load more HOT NEWS Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum... Anal Cancer Advances Open Door to Screening and Prevention Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in...
